Fasken Martineau DuMoulin LLP

Fasken Martineau DuMoulin LLP

June 07, 2006 08:00 ET

Fasken Martineau DuMoulin LLP: Protox Therapeutics to Present at Technology and Life Sciences Forum

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - June 7, 2006) - Protox Therapeutics Inc. (TSX VENTURE:PRX) announced today that Dr. Fahar Merchant, Protox's President and Chief Executive Officer, will be a featured presenter at the 2006 Fasken Martineau Technology and Life Sciences Forum to be held June 13, 2006 at the Hyatt Regency Vancouver in British Columbia.

The 2006 Fasken Martineau Technology and Life Sciences Forum is a full day event in which public companies from British Columbia's technology and life sciences industries present their technology and progress to members of the investment community.

Dr. Merchant's presentation will take place at 10:00a.m. PST in the Regency A Room. For more information about the forum, visit the forum website at www.faskenforum.com or contact Jennifer Despins at Fasken Martineau directly at 604-631-3296 or faskenforum@van.fasken.com.

About Protox Therapeutics

Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. Through the company's PORxin™ technology platform, therapeutic candidates are generated by engineering the naturally occurring protein, pro-aerolysin. These proteins become potent anti-cancer agents when activated at a tumor site by specific proteases produced by cancer cells. Once activated, the drug punches holes in the cancer cells causing the contents to leak out and ultimately, cell death. Protox is in Phase I clinical trials with the lead compound, PRX302, for the treatment of localized prostate cancer. PRX302 is also being developed for treatment of benign prostatic hyperplasia.

This press release contains certain forward-looking statements respecting the Company's business, capital, research and development, and potential future products, which statements can be identified by the use of forward looking terminology, such as "expect", "to generate", "moving forward", "intends", "committed to", "moving", "developing", "believe" or the negative thereof or any other variations thereon or, or that events or conditions "will", "can", "to", "may", "could" or "should" occur, or comparable terminology referring to future events or results. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including, without limitation, the need for extensive additional research and development, which is costly and time-consuming and may not produce anticipated or useful results; scientific research and development risks; the risk of technical obsolescence; intellectual property risks; manufacturing and marketing risks; partnership/strategic alliance risks; the effect of competition; the need for regulatory approvals, including without limitation, FDA approvals, which is not assured; product liability and insurance risks; the need for future human clinical trials, the occurrence and success of which is not assured; changes in business strategy or development plans; and the need for additional capital, which may not be obtained; and the fact that the Company may not produce any products or if it does, that such products may not be commercially successful; any of which could cause actual results to vary materially from current results or the Company's anticipated future results. See the Company's prospectus and other documents filed with the TSX Venture Exchange and the Canadian Securities Administrators at www.sedar.com from time to time for a further discussion of these and other important risks and uncertainties that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no responsibility to update the information contained in this press release.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this press release.

Contact Information